Prostacyclin mimetics inhibit DRP1-mediated pro-proliferative mitochondrial fragmentation in pulmonary arterial hypertension

• Published in: Vascular pharmacology 2023-08, Vol.151, p.107194-107194, Article 107194
• Main Authors: Abu-Hanna, Jeries, Anastasakis, Evangelos, Patel, Jigisha A., Eddama, Mohammad Mahmoud Rajab, Denton, Christopher P., Taanman, Jan-Willem, Abraham, David, Clapp, Lucie H.
• Format: Article
• Language: English
• Subjects: Cell Proliferation; Dynamin-related protein 1; Dynamins - metabolism; Dynamins - pharmacology; Humans; Mitochondria; Mitochondrial Dynamics; Prostacyclin; Pulmonary arterial hypertension; Pulmonary Arterial Hypertension - metabolism; Pulmonary arterial smooth muscle cells; Pulmonary Artery - metabolism
• ISSN: 1537-1891; 1879-3649
• DOI: 10.1016/j.vph.2023.107194

Pulmonary arterial hypertension (PAH) is a rare cardiopulmonary disorder, involving the remodelling of the small pulmonary arteries. Underlying this remodelling is the hyper-proliferation of pulmonary arterial smooth muscle cells within the medial layers of these arteries and their encroachment on the lumen. Previous studies have demonstrated an association between excessive mitochondrial fragmentation, a consequence of increased expression and post-translational activation of the mitochondrial fission protein dynamin-related protein 1 (DRP1), and pathological proliferation in PASMCs derived from PAH patients. However, the impact of prostacyclin mimetics, widely used in the treatment of PAH, on this pathological mitochondrial fragmentation remains unexplored. We hypothesise that these agents, which are known to attenuate the proliferative phenotype of PAH PASMCs, do so in part by inhibiting mitochondrial fragmentation. In this study, we confirmed the previously reported increase in DRP1-mediated mitochondrial hyper-fragmentation in PAH PASMCs. We then showed that the prostacyclin mimetic treprostinil signals via either the Gs-coupled IP or EP2 receptor to inhibit mitochondrial fragmentation and the associated hyper-proliferation in a manner analogous to the DRP1 inhibitor Mdivi-1. We also showed that treprostinil recruits either the IP or EP2 receptor to activate PKA and induce the phosphorylation of DRP1 at the inhibitory residue S637 and inhibit that at the stimulatory residue S616, both of which are suggestive of reduced DRP1 fission activity. Like treprostinil, MRE-269, an IP receptor agonist, and butaprost, an EP2 receptor agonist, attenuated DRP1-mediated mitochondrial fragmentation through PKA. We conclude that prostacyclin mimetics produce their anti-proliferative effects on PAH PASMCs in part by inhibiting DRP1-mediated mitochondrial fragmentation. [Display omitted]